Entering text into the input field will update the search result below

Galena Biopharma jumps on Oppenheimer initiation seeing 63% upside

Nov. 26, 2013 10:24 AM ETSELLAS Life Sciences Group, Inc. (SLS) StockSLSBy: 2, SA News Editor
  • Shares of Galena Biopharma (GALE +9%) jump after Oppenheimer initiates the oncology-focused biotech at Outperform with a PT of $6.
  • The firm's target implies an upside of 63% from yesterday's close.
  • Analyst Boris Peaker thinks shares could reach $6 in the next 12-18 months. NeuVax's reported Phase I and II data is "encouraging," as is the ~$5B global commercial opportunity for the drug.
  • Peaker places a $6 valuation on NeuVax alone and sees Abstral's "good traction in the initial stages of launch" as added value, given that "it is a competitive fentanyl formulation and will find a clear niche in the market."

Recommended For You

More Trending News

About SLS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SLS--
SELLAS Life Sciences Group, Inc.